CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx, Inc. has announced that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. The policy covers Barostim for patients with FDA-approved indications and participants in the BENEFIT-HF trial, representing a significant milestone for the company’s efforts to broaden access to heart failure treatment.
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states.